Separation method of gram-negative bacterium outer membrane vesicles (OMVs)

By using a separation method that specifically binds nanoparticles to the phospholipid components of OMVs, the problems of structural damage and insufficient purity in traditional separation techniques have been solved, achieving efficient and low-cost OMV separation, which is applicable to the fields of biomedicine and disease diagnosis.

CN119020197AInactive Publication Date: 2024-11-26OCEAN UNIV OF CHINA
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411034129.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing technologies are insufficient for the efficient and low-cost isolation and purification of outer membrane vesicles (OMVs) of Gram-negative bacteria, and traditional methods can lead to structural damage or insufficient purity.

Method used

A separation method employing the specific binding of nanoparticles with the phospholipid components of OMVs includes crude extraction of OMVs, complex formation, purification, elution, and separation steps. The method utilizes the Lewis acid sites of nanoparticles to form stable complexes with the phosphate groups of OMVs, and achieves efficient separation through centrifugation and ultrafiltration.

Benefits of technology

It improves the separation efficiency and purity of OMVs, maintains their biological activity, simplifies the operation process, reduces costs, is suitable for large-scale production, and promotes applications in the fields of biomedicine and disease diagnosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020197A_ABST
    Figure CN119020197A_ABST
Patent Text Reader

Abstract

The invention discloses a separation method of gram-negative bacterium outer membrane vesicles (OMVs), and belongs to the technical field of molecular biologica.According to the separation method, efficient separation and purification of the OMVs are achieved through nano-particles, characteristic adsorption and purification of the OMVs are achieved through Lewis acid sites on the surfaces of nano-particle microspheres, and the OMVs are separated and purified through the Lewis acid sites on the surfaces of the nano-particle microspheres. The OMVs are rapidly eluted from the surfaces of the nano-particle microspheres by using an eluent without damaging the structures of the OMVs, and characterization observation is carried out by adopting polyacrylamide gel electrophoresis (SDS-PAGE), dynamic light scattering (DLS) and a transmission electron microscope (TEM). Compared with a traditional ultracentrifugation and ultrafiltration method, the technology has the advantages that the separation efficiency and purity are remarkably improved, meanwhile, the biological activity and structural integrity of the OMVs are reserved, the operation process is simplified, the cost is reduced, technology popularization and industrial application are promoted, and the technology particularly shows huge economic potential in the field of biological medicine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of molecular biotechnology, and in particular relates to a method for separating Gram-negative bacteria outer membrane vesicles (OMVs). Background Art

[0002] OMVs, as nanoscale membrane structures released by Gram-negative bacteria, have important biological functions, including but not limited to the delivery of genetic material, virulence factors, and participation in host-pathogen interactions. In recent years, OMVs have demonstrated disruptive innovative application potential and market prospects in the fields of vaccine development, disease diagnosis, and drug delivery. It can be foreseen that in the next few years, OMVs will occupy an important position in medicine, biotechnology, and other high-tech industries, and bring significant economic benefits.

[0003] Despite the wide potential applications of OMVs, their effective separation and purification face multiple challenges. Traditional methods, such as ultracentrifugation, ultrafiltration, size exclusion chromatography, and density gradient centrifugation, each have their own advantages, but they also expose a series of limitations. For example, ultracentrifugation not only relies on expensive equipment and is not suitable for processing large amounts of samples, but excessive centrifugation can also damage the structure and function of OMVs. For another example, although ultrafiltration has a high recovery rate, the separation purity is limited. Therefore, there is currently no OMVs separation technology that is suitable for large doses, low cost, and high purity.

[0004] The present invention aims to provide an innovative separation strategy based on nanoparticles, which fully utilizes the specific interaction between nanoparticles and phospholipid molecules to achieve efficient, rapid and large-scale preparation of OMVs. Summary of the invention

[0005] The object of the present invention is to provide a method for separating Gram-negative bacteria outer membrane vesicles (OMVs) to solve the problems raised in the above background technology.

[0006] To achieve the above object, the present invention provides the following technical solution: a method for separating Gram-negative bacterial outer membrane vesicles (OMVs), characterized by comprising the following steps:

[0007] (a) Crude extraction of OMVs;

[0008] (b) Formation of OMVs-nanoparticle complexes;

[0009] (c) Purification of OMVs-nanoparticle complexes;

[0010] (d) Elution of OMVs;

[0011] (e) Isolation and storage of OMVs.

[0012] Preferably, the OMVs are derived from Gram-negative bacteria grown under various conditions.

[0013] Preferably, the size range of the nanoparticles is 20 to 1000 nm; the nanoparticles have Lewis acid sites; the Lewis acid sites can form a stable complex with the phosphate groups in OMVs; the nanoparticles containing Lewis acid sites include but are not limited to metal organic framework (MOF) nanoparticles, oxide nanoparticles, carbon-based catalysts, mesoporous silicon-based nanoparticles, and inorganic-polymer nanocomposites.

[0014] Preferably, in step (a), the OMVs are crudely extracted and then mixed and incubated with the nanoparticles, including: the crude extraction step of OMVs is to remove the bacteria and solid contents of the solution containing OMVs under centrifugal conditions.

[0015] Preferably, in step (b), the nanoparticles and OMVs are mixed and incubated at 4-37° C. for 10-60 minutes to form OMVs-nanoparticles.

[0016] Preferably, the purification step of OMVs-nanoparticles in step (c) is to wash with a washing solution and separate the OMVs-nanoparticle complex by centrifugation; the centrifugation speed is preferably 3000-12000 rpm; the washing solution is selected from one or more of the following components: phosphate buffered saline (PBS), Tris-HCl, ammonia water, triethanolamine, sodium chloride (NaCl), sodium azide (NaN3), Tween 20 (tween 20), and deionized water.

[0017] Preferably, in step (d), the separated OMVs-nanoparticle complex is dispersed in an eluent for secondary incubation; the eluent is selected from one or more of the following components: phosphate buffered saline (PBS), Tris-HCl, ammonia water, triethanolamine, sodium chloride (NaCl), potassium chloride (KC1), potassium iodide (KI), sodium azide (NaN3), Tween 20, and deionized water.

[0018] Preferably, in the step (e), the separation of OMVs is performed by separating OMVs from nanoparticles by centrifugation at a speed of 3000 to 12000 rpm, and a 100 kD ultrafiltration column is used to replace the solvent of the OMVs with a storage solvent; the storage solvent is selected from one or more of the following components: phosphate buffered saline (PBS), Tris-HCl, ammonia water, triethanolamine, sodium chloride (NaCl), sodium azide (NaN3), Tween 20, deionized water, bovine serum albumin solution, dextran solution, sialic acid solution, glycerol aqueous solution, dimethyl sulfoxide, Proclin.

[0019] Compared with the prior art, the present invention has the following beneficial effects:

[0020] First, the separation efficiency and purity of OMVs are significantly improved. Although traditional separation technologies, such as ultracentrifugation and ultrafiltration, can achieve the separation of OMVs, they have obvious shortcomings in separation efficiency and purity. Ultracentrifugation often leads to the destruction of the OMVs structure and affects its biological activity; while ultrafiltration is limited by membrane clogging and separation purity problems. The present invention utilizes the specific binding between nanoparticles and the phospholipid components of OMVs to achieve efficient capture of OMVs, which not only improves the separation efficiency, but also effectively avoids the common structural damage in traditional methods, ensuring the biological activity and structural integrity of OMVs. Secondly, the separation process is simplified and the operation difficulty is reduced. Traditional separation technology usually requires complex operation steps and special equipment, such as ultra-high-speed centrifuges, which not only increases the experimental cost, but also limits the popularization of the technology. In contrast, the nanoparticle-mediated separation method proposed in the present invention is simpler to operate, does not need to rely on expensive equipment, reduces the technical threshold, and is conducive to the wide application of OMVs separation technology in scientific research institutions and industrial production. Thirdly, the separation cost is reduced and the economic benefit is improved. Most of the traditional OMVs separation methods are suitable for the preparation of a small amount of OMVs, while the present invention can efficiently capture a large number of OMVs using nanoparticles, which has important economic significance for the large-scale production of OMVs, especially for large-scale applications in the fields of biomedicine and disease diagnosis. The present invention not only provides an efficient separation technology, but also lays a solid foundation for subsequent OMVs analysis, structural characterization and functional research. The maintenance of the biological activity and structural integrity of OMVs also provides potential biomarkers and drug carriers for early diagnosis and targeted treatment of diseases, and promotes the progress and development of OMVs-related research fields. In summary, the nanoparticle-based OMVs separation and identification technology proposed in the present invention not only overcomes the limitations of the existing technology, but also shows significant advantages in separation efficiency, ease of operation, cost-effectiveness, and biological research and application potential of OMVs, and has important scientific value and broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 This is a graph showing the effect of separation rotation speed on nanoparticle recovery rate in the present invention;

[0022] Figure 2 is a graph showing the relationship between the dosage of nanoparticles used in the present invention and the concentration of separated OMVs;

[0023] Figure 3 is a graph showing the relationship between the incubation time and the concentration of separated OMVs of the present invention;

[0024] Figure 4This is a western blot image of OMVs separated by the present invention;

[0025] Figure 5 This is a particle size diagram of OMVs separated by the present invention;

[0026] Figure 6 is the Zeta potential diagram of OMVs separated by the present invention;

[0027] Figure 7 This is an electron micrograph of the OMVs eluted in the present invention. DETAILED DESCRIPTION

[0028] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0029] See also Figure 1-Figure 7 The present invention provides a method for separating Gram-negative bacterial outer membrane vesicles (OMVs), comprising the following steps:

[0030] (a) Crude extraction of OMVs;

[0031] (b) Formation of OMVs-nanoparticle complexes;

[0032] (c) Purification of OMVs-nanoparticle complexes;

[0033] (d) Elution of OMVs;

[0034] (e) Isolation and storage of OMVs.

[0035] Furthermore, the key steps include separation using nanoparticles, as well as a series of carefully designed extraction and separation processes. Compared with traditional methods, such as ultracentrifugation, ultrafiltration, size exclusion chromatography and density gradient centrifugation, the separation technology of the present invention not only significantly improves the separation efficiency of OMVs, but also maintains the biological activity and structural integrity of OMVs. The use of nanoparticles, especially their preferred size range (20 to 1000 nm), can efficiently capture OMVs. The innovation of this technology is that it overcomes the problem of relying on large and expensive instruments and equipment in traditional separation technology, and provides pure and complete samples for the in-depth study and application of OMVs. Simple and fast separation and extraction experimental methods and low-cost materials help to improve experimental efficiency and speed, reduce the overall operating costs of experiments and production, simplify the experimental process, reduce dependence on equipment and reagents, and greatly promote research progress in related fields.

[0036] In this example, OMVs were derived from Gram-negative bacteria grown under various conditions.

[0037] Furthermore, Gram-negative bacteria are preferably Escherichia coli, Shigella and Neisseria, as well as attenuated bacteria and engineered strains, which are mainly used in anti-tumor activity research, gene editing, and the production of bispecific antibodies.

[0038] In this embodiment, the size range of the nanoparticles is 20 to 1000 nm; the nanoparticles have Lewis acid sites; the Lewis acid sites form a stable complex with the phosphate groups in the OMVs; the nanoparticles containing Lewis acid sites include but are not limited to metal organic framework (MOF) nanoparticles, oxide nanoparticles, carbon-based catalysts, mesoporous silicon-based nanoparticles, and inorganic-polymer nanocomposites.

[0039] Furthermore, the size range of the nanoparticles is limited to 20 to 1000 nm. This size selection is based on the specific interaction between the nanoparticles and the phospholipid components of OMVs, which maximizes the capture efficiency of OMVs. The nanoparticles have a large specific surface area, and the surface energy and surface tension increase dramatically, which makes the nanoparticles perform well in catalysis and other aspects. In addition, the larger contact area helps to improve the stability of the material and enhance its activity. By controlling the size of the nanoparticles, the present invention can achieve rapid separation of OMVs through simple multiple centrifugation, thereby greatly shortening the experimental cycle, improving work efficiency, and reducing separation costs. This size optimization strategy provides a reference standard for the efficient separation of OMVs and promotes the standardization and normalization of OMVs-related research.

[0040] In this embodiment, in step (a), the OMVs are crudely extracted and then mixed and incubated with the nanoparticles, including: the crude extraction step of OMVs is to remove the bacteria and solid contents of the solution containing OMVs under centrifugal conditions.

[0041] Furthermore, in order to promote the full attachment of OMVs to nanoparticles and prevent the structural performance of OMVs that may be changed due to excessive temperature, a suitable environment is not only conducive to maintaining the biological activity of OMVs, but also can enhance the interaction between nanoparticles and OMVs, thereby improving the separation efficiency. By controlling the incubation time, it can be ensured that OMVs have enough time to contact with nanoparticles to achieve the best adsorption effect, while avoiding nonspecific adsorption that may be caused by long-term incubation, and ensuring the purity of separated OMVs.

[0042] In this embodiment, in step (b), the nanoparticles and OMVs are mixed and incubated at 4-37° C. for 10-60 minutes to form OMVs-nanoparticles.

[0043] Furthermore, the amount of nanoparticles added is 0.1 mg / mL to 5 mg / mL.

[0044] In this embodiment, the purification step of OMVs-nanoparticles in step (c) is to wash with a washing solution and separate the OMVs-nanoparticle complex by centrifugation; the centrifugation speed is preferably 3000-12000 rpm. The washing solution is selected from one or more of the following components: phosphate buffered saline (PBS), Tris-HCl, ammonia water, triethanolamine, sodium chloride (NaCl), sodium azide (NaN3), Tween 20 (tween 20), and deionized water.

[0045] Furthermore, the cleaning solution is selected from one or more of the following components: 0.01-0.2M phosphate buffer, 0.01M-0.5M Tris-HCl, 0.01M-10M ammonia water, 5mM-300mM triethanolamine, 5mM-300mM sodium chloride, 0.01-0.1% sodium azide (NaN3), and 0.01%-0.05% Tween 20.

[0046] In this embodiment, in step (d), the separated OMVs-nanoparticle complex is dispersed in an eluent for secondary incubation; the eluent is selected from one or more of the following components: phosphate buffered saline (PBS), Tris-HCl, ammonia water, triethanolamine, sodium chloride (NaC1), potassium chloride (KC1), potassium iodide (KI), sodium azide (NaN3), Tween 20, and deionized water; the ultrafiltration system is a 5kD to 100kD molecular retention system.

[0047] Furthermore, the eluent is selected from one or more of the following components: 0.01-0.2M phosphate buffer, 0.01M-0.5M Tris-HCl, 0.01M-10M ammonia water, 5mM-500mM triethanolamine, 5mM-300mM sodium chloride, 5mM-300mM potassium chloride (KC1), 5mM-500mM potassium iodide (KI), 0.01-0.1% sodium azide (NaN3), and 0.01%-0.05% Tween 20.

[0048] In this embodiment, the centrifugal separation of nanoparticles in step (e) includes: centrifugal separation of OMVs in an eluent, the obtained supernatant is quickly replaced with a storage solvent using an ultrafiltration system, and then washed several times with the storage solvent, and the OMVs in the filter tube are collected for further research; the storage solution is selected from one or more of the following components: phosphate buffered saline (PBS), Tris-HCl, ammonia water, triethanolamine, sodium chloride (NaCl), sodium azide (NaN3), Tween 20 (tween20), deionized water, bovine serum albumin solution, dextran solution, sialic acid solution, glycerol aqueous solution, dimethyl sulfoxide, Proclin.

[0049] Further, the storage solution is selected from one or more of the following components: 0.01-0.2M phosphate buffer, 0.01M-0.5M Tris-HCl, 0.01M-0.1M ammonia water, 5mM-300mM triethanolamine, 5mM-300mM sodium chloride, 0.01-0.1% sodium azide (NaN3), 0.01%-0.05% Tween 20, 1-10g / L bovine serum albumin solution, dextran 10-70 solution, 0.01-5% sialic acid solution, 25%-50% glycerol aqueous solution, 5%-10% dimethyl sulfoxide, and 0.02%-0.3% Proclin.

[0050] The working principle and use process of the present invention:

[0051] First, the target Gram-negative bacteria were cultured under appropriate conditions, such as growing on agar plates at 24°C to 45°C, then the colonies were transferred to liquid culture medium and continued to grow overnight at the same temperature to promote the formation of OMVs. Next, the supernatant was collected by centrifuging the bacterial solution at 3000 rpm for 20 min, and then centrifuged at 12000 rpm for 20 min to continue collecting the supernatant. The supernatant was first filtered with a 0.45 μm filter membrane, and then the filtrate was filtered with a 0.22 μm filter membrane to remove bacteria and dead cells. The supernatant was concentrated using a 100 kD tangential flow system in an ice bath, and 1 L of supernatant was concentrated to 100 mL. 10 mg, 30 mg, 50 mg, and 10 0mg and 150mg of TiO2 nanoparticles were mixed and incubated to promote the full attachment of OMVs on its surface. The size of the nanoparticles was preferably 20-1000nm. The OMVs-TiO2 nanoparticles were separated from the solution by centrifugation at 3,000rpm for 20min, and then thoroughly washed three times with a washing solution PBS to remove any non-specifically bound molecules. A 10% ammonia eluent was used to incubate at 4°C for 10min to fully elute the OMVs. Subsequently, the supernatant was quickly replaced with a storage solution PBS through an ultrafiltration system. The characteristic proteins of the isolated bacterial extracellular vesicles, such as OmpA, were characterized by Western blot. Figure 4 It can be clearly seen that the bacterial extracellular vesicles obtained by the present invention and the ultra-high speed centrifugation method have a unique OmpA band, which proves that the present invention can effectively separate bacterial extracellular vesicles. The morphology and integrity of OMVs were observed under an accelerating voltage using a transmission electron microscope (TEM) to confirm that their structure was not damaged. At the same time, the particle size distribution and charge state of OMVs were measured by a nanoparticle size and zeta potential meter, and the peak shape was relatively sharp. The purity of the bacterial outer membrane vesicles separated from the surface was high. These data are of great significance for understanding the physicochemical properties of OMVs and their stability in different environments. Finally, all the obtained data were comprehensively analyzed to evaluate the effects of the separation and purification process and the quality of OMVs. Based on this information, we can further optimize the separation conditions, improve the purity and recovery rate, and explore the application potential of OMVs in the fields of disease diagnosis and drug delivery.

[0052] The above shows and describes the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. A method for isolating Gram-negative bacterial outer membrane vesicles (OMVs), characterized in that The following steps are involved: (a) Crude extraction of OMVs; (b) Formation of OMVs-nanoparticle complexes; (c) Purification of OMVs-nanoparticle complexes; (d) Elution of OMVs; (e) Isolation and storage of OMVs.

2. The method for isolating Gram-negative bacterial outer membrane vesicles (OMVs) according to claim 1, characterized in that: The OMVs are derived from Gram-negative bacteria grown under various conditions.

3. The method for isolating Gram-negative bacterial outer membrane vesicles (OMVs) according to claim 1, characterized in that: The size range of the nanoparticles is 20 to 1000 nm; the nanoparticles have Lewis acid sites; the Lewis acid sites can form a stable complex with the phosphate groups in OMVs; the nanoparticles containing Lewis acid sites include but are not limited to metal organic framework (MOF) nanoparticles, oxide nanoparticles, carbon-based catalysts, mesoporous silicon-based nanoparticles, and inorganic-polymer nanocomposites.

4. The method for isolating Gram-negative bacterial outer membrane vesicles (OMVs) according to claim 1, characterized in that: In the step (a), the OMVs are crudely extracted and then mixed and incubated with the nanoparticles, including: the crude extraction step of the OMVs is to remove the bacteria and solid contents of the solution containing the OMVs under centrifugal conditions.

5. The method for isolating Gram-negative bacterial outer membrane vesicles (OMVs) according to claim 1, characterized in that: In the step (b), the nanoparticles and OMVs are mixed and incubated at 4-37° C. for 10-60 minutes to form OMVs-nanoparticles.

6. The method for isolating Gram-negative bacterial outer membrane vesicles (OMVs) according to claim 1, characterized in that: The purification step of OMVs-nanoparticles in step (c) is to wash with a washing solution and separate the OMVs-nanoparticle complex by centrifugation; the centrifugation speed is preferably 3000-12000 rpm; the washing solution is selected from one or more of the following components: phosphate buffered saline (PBS), Tris-HCl, ammonia water, triethanolamine, sodium chloride (NaCl), sodium azide (NaN3), Tween 20 (tween 20), and deionized water.

7. The method for isolating Gram-negative bacterial outer membrane vesicles (OMVs) according to claim 1, characterized in that: In the step (d), the separated OMVs-nanoparticle complex is dispersed in an eluent and incubated for a second time; the eluent is selected from one or more of the following components: phosphate buffered saline (PBS), Tris-HCl, ammonia water, triethanolamine, sodium chloride (NaCl), potassium chloride (KC1), potassium iodide (KI), sodium azide (NaN3), Tween 20 (tween 20), and deionized water.

8. The method for isolating Gram-negative bacterial outer membrane vesicles (OMVs) according to claim 1, characterized in that: In the step (e), the OMVs are separated from the nanoparticles by centrifugation, the centrifugal speed is 3000-12000 rpm, and the solvent of the OMVs is replaced with a storage solvent using a 100kD ultrafiltration column; the storage solvent is selected from one or more of the following components: phosphate buffered saline (PBS), Tris-HCl, ammonia water, triethanolamine, sodium chloride (NaCl), sodium azide (NaN3), Tween 20, deionized water, bovine serum albumin solution, dextran solution, sialic acid solution, glycerol aqueous solution, dimethyl sulfoxide, Proclin.

Citation Information

Patent Citations

  • Method for separating exosomes from urine

    CN112813027A

  • Dual-functional MOF material and preparation and application thereof

    CN113999399A

  • Method for extracting exosome based on transition metal oxyhydroxide

    CN115992092A

  • An improved process for producing outer membrane vesicles

    US20210238540A1

  • Extracellular vesicle purification material and purification method

    US20230258629A1